Newsroom
May 21, 2013:
iCo Therapeutics Closes $3.4 Million Financing
May 10, 2013:
iCo Therapeutics to Raise $3.2 Million
May 9, 2013:
iCo Therapeutics Announces Overnight Marketed Equity Offering
Apr 25, 2013:
iCo Therapeutics Announces Year End 2012 Financial Results
Feb 14, 2013:
iCo Therapeutics Ranked Number One in Technology & Life Sciences on 2013 TSX Venture 50
Feb 5, 2013:
iCo Therapeutics to Present at the 15th Annual BIO CEO & Investor Conference
Jan 22, 2013:
iCo Therapeutics Grants Options to Directors, Officers and Employees
Jan 3, 2013:
iCo Therapeutics Announces Positive iCo-007 Phase 2 Clinical Update
Nov 29, 2012:
iCo Therapeutics Announces Third Quarter 2012 Financial Results
Oct 12, 2012:
iCo Therapeutics' Oral Amphotericin B Delivery System to be Presented at AAPS with Updated Patent Position
Sep 5, 2012:
iCo Therapeutics to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
Aug 29, 2012:
iCo Therapeutics Announces Second Quarter 2012 Financial Results
Jul 13, 2012:
iCo Therapeutics Closes $2.55 Million Financing
Jul 5, 2012:
iCo Therapeutics to Raise $2.55 Million
Jul 4, 2012:
iCo Therapeutics Announces Overnight Marketed Equity Offering
May 31, 2012:
iCo Therapeutics receives funding from the Government of Canada for the pre-clinical and clinical development of its Oral Amphotericin B Delivery System for the treatment of HIV/AIDS
May 30, 2012:
iCo Therapeutics Announces First Quarter 2012 Financial Results
Apr 16, 2012:
iCo Therapeutics Announces Year End 2011 Financial Results
Mar 28, 2012:
iCo Therapeutics and JDRF Team Up to Support Phase II Clinical Trial iDEAL for Diabetic Macular Edema
Mar 27, 2012:
iCo Therapeutics CEO to Present at Retinal Physician Symposium 2012
Mar 5, 2012:
iCo Therapeutics Appoints Douglas Janzen to Board of Directors
Jan 17, 2012:
iCo Therapeutics Retains Crescendo Communications
Dec 5, 2011:
iCo Therapeutics Announces Execution of Equity Line Facility Agreement
Nov 18, 2011:
iCo Therapeutics Announces Third Quarter 2011 Financial Results
Nov 2, 2011:
iCo Therapeutics Closes $1,115,000 Non-Brokered Private Placement
Oct 24, 2011:
iCo Therapeutics Oral Amphotericin B Delivery System to be Presented at AAPS
Oct 20, 2011:
iCo Therapeutics CEO to Present at the Ophthalmology Innovation Summit
Sep 27, 2011:
iCo Therapeutics Grants Options to Directors, Officers and Employees
Sep 26, 2011:
iCo Therapeutics and JDRF Partner to Investigate iCo-007 in Diabetic Macular Edema
Sep 13, 2011:
iCo Therapeutics CEO to Present & Act as Co-Chairperson at the 4th Annual Drug Repositioning and Pipeline Enhancement Conference
Aug 29, 2011:
iCo Therapeutics Announces Second Quarter 2011 Financial Results
Aug 15, 2011:
iCo Therapeutics Announces Key iCo-007 Clinical Development Milestone
Jul 23, 2011:
iCo Therapeutics Announces Resignation of John Clement, Chief Technology and Development Officer and Director
Jul 19, 2011:
iCo Therapeutics Engages The Equicom Group
Jul 12, 2011:
iCo Therapeutics CMO to Present at The Drug Repositioning Conference
Jun 29, 2011:
iCo Therapeutics Announces First Quarter 2011 Financial Results
Jun 24, 2011:
iCo Therapeutics Executes Bertilimumab License with Immune Pharmaceuticals
May 31, 2011:
iCo Therapeutics CEO to Present & Participate in Panel at BioFinance 2011
May 13, 2011:
iCo Therapeutics Inc. Engages Ora for Ophthalmic Clinical & Regulatory Guidance
Apr 29, 2011:
iCo Therapeutics Announces Year-End 2010 Financial Results
Apr 14, 2011:
iCo Therapeutics Inc. Secures $10 Million Equity Line Facility
Feb 23, 2011:
iCo Therapeutics Inc. iCo-007 Program to be Presented & CEO to Sit on Panel at Retinal Physician Symposium 2011
Feb 22, 2011:
iCo Therapeutics Inc. Completes iCo-007 Phase 2 Clinical Supply Manufacturing
Dec 24, 2010:
iCo Therapeutics Extends Investor Relations Engagement with The Trout Group
Dec 8, 2010:
iCo Therapeutics Grants License Option for Bertilimumab (iCo-008) Systemic Uses to Immune Pharmaceuticals for US$33 Million Plus Royalties
Nov 26, 2010:
iCo Therapeutics Reports Third Quarter 2010 Financial Results
Oct 13, 2010:
iCo Therapeutics Selected as Canada's Top 10TM Competition Winner
Sep 29, 2010:
iCo Therapeutics Oral Amphotericin Program Receives FDA Orphan Drug Status
Sep 22, 2010:
iCo Therapeutics Appoints Infectious Disease Experts to Scientific Advisory Board
Aug 27, 2010:
iCo Therapeutics Announces Second Quarter 2010 Financial Results
Jul 26, 2010:
iCo Therapeutics Inc. receives Health Canada Clearance to Conduct Phase II DME Trial with iCo-007
May 28, 2010:
iCo Therapeutics Inc. enters into Investor Relations Engagements with The Trout Group and Sector Speak
May 26, 2010:
iCo Therapeutics Announces First Quarter 2010 Financial Results
May 25, 2010:
iCo Therapeutics Inc. enters into Technology Transfer Agreement with Isis Pharmaceuticals, Inc. for iCo-007
May 17, 2010:
iCo Therapeutics iCo-007 Phase I Clinical Trial Meets Primary Endpoint
Apr 29, 2010:
iCo Therapeutics Announces Year-End 2009 Financial Results
Apr 28, 2010:
iCo Therapeutics Inc. engages Susan Koppy to spearhead iCo-007 out-licensing
Apr 22, 2010:
iCo-007 for Diffuse Diabetic Macular Edema to be Presented at Retinal Physician Symposium 2010
Apr 12, 2010:
iCo Therapeutics Inc. Recognized by BIOTECanada with Gold Leaf Award
Dec 3, 2009:
iCo Therapeutics iCo-007 Overview to be Presented at the 8th International Symposium on Ocular Pharmacology and Therapeutics
Nov 26, 2009:
iCo Therapeutics Q3 2009 Financial Results
Aug 21, 2009:
iCo Therapeutics Q2 2009 Financial Results
Jul 21, 2009:
iCo Therapeutics Appoints Infectious Disease MD to Scientific Advisory Board
Jul 16, 2009:
iCo Therapeutics Closes Non-Brokered Private Placement
Jul 7, 2009:
iCo Therapeutics Diabetic Macular Edema Clinical Trial Update
Nov 18, 2008:
iCo Therapeutics Oral Amphotericin B Poster at AAPS
Nov 17, 2008:
iCo Therapeutics Third Quarter Financial Results
Nov 7, 2008:
iCo Therapeutics Oral Amphotericin B Effective Against Visceral Leishmaniasis
Oct 9, 2008:
iCo Therapeutics Provides iCo-009 (Oral Amphotericin B) Pharmacokinetic Results
Oct 1, 2008:
iCo Therapeutics Selected as Canada's Top 10TM Competition Winner
Sep 29, 2008:
iCo Therapeutics to Present at BioContact Québec
Sep 22, 2008:
iCo Therapeutics Provides Interim Trial Results (Diffuse Diabetic Macular Edema)
Sep 4, 2008:
iCo Therapeutics Outlines Steps to First iCo-009 Human Clinical Trial
Aug 28, 2008:
iCo Therapeutics Second Quarter Financial Results
Jul 8, 2008:
iCo Therapeutics Appoints Mr. Noel Hall and Dr. Christian Fibiger to Board
Jun 26, 2008:
iCo Therapeutics Reports New iCo-009 (Oral Amphotericin B) Preclinical Results
Jun 9, 2008:
iCo Therapeutics Closes $1,140,450 Financing
Jun 2, 2008:
iCo Therapeutics Announces $1,140,450 Financing
May 30, 2008:
iCo Therapeutics First Quarter Financial Results
May 7, 2008:
iCo Therapeutics Acquires Worldwide Rights to iCo-009 (Oral Amphotericin B)
May 5, 2008:
iCo Therapeutics to Present at BioFinance 2008
Apr 28, 2008:
iCo Therapeutics Year-End 2007 Financial Results
Apr 25, 2008:
iCo Therapeutics iCo-007 Diabetic Macular Edema Poster Presentation at ARVO
Apr 21, 2008:
iCo Therapeutics Announces iCo-009 (Oral Amphotericin B) FDA Meeting
Mar 17, 2008:
iCo Therapeutics iCo-009 (Oral Amphotericin B) Published in Leading Drug Delivery Journal
Mar 10, 2008:
iCo Therapeutics Provides iCo-008 Phase II Clinical Update
Feb 27, 2008:
iCo Therapeutics Announces CMO Invited to Present at International Ocular Conference
Jan 21, 2008:
iCo Therapeutics Provides iCo-009 (Oral Amphotericin B) Update
Dec 31, 2007:
iCo Therapeutics Inc. and Beanstalk Capital Ltd. Announce Completion of Arrangement
Oct 31, 2007:
Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement
Oct 16, 2007:
Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc.
Oct 9, 2007:
Isis Receives $1.25 Million Milestone Payment From iCo for Initiation of Phase 1 Study of iCo-007
Jan 22, 2007:
iCo Therapeutics Receives FDA Clearance to Initiate Clinical Trial in Diabetic Macular Edema
Jan 10, 2007:
iCo Therapeutics announces licensing deal
Jan 8, 2007:
Cambridge Antibody Tech. licenses monoclonal antibody for treatment of allergy disorders to iCo
Copyright 2010 ICO Therapeutics | Disclaimer